arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

ALUMIS INC.

ALMS
$7.45 ▼ -0.65 (-8.09%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
15 Visible periods
23 Metrics
Peer-ranked Benchmarks
Price Chart
31
Health
Poor
Bearish
auto_awesome

Analytical Summary

ALUMIS INC. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $951.3M
Dividend Yield
Revenue Growth -37.7%
Op. Margin
ROIC -32.5%
FCF / Share $-0.64
Trailing P/E
Price / Book 2.1x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Sep 23, 2026.

15-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$1.66M
↓ -37.7%
Net Income Profit after all expenses
$-93.05M
↑ +6.0%
FCF / Share Free cash flow per share
$-0.64
↑ +54.2%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
11
Cash Quality
80

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 4 years · 15 quarters